The effectiveness of oral hypoglycemic agents in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. -Multiple comparison, Dapagliflozin, Pioglitazone vs Glimepiride
Not Applicable
- Conditions
- onalcoholic fatty liver disease patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000021291
- Lead Sponsor
- Kawasaki Medical SchoolKawasaki Medical School Devision of Diabetes, Endocrinology and Metabolism
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
A) Under 20 years old B) Treatment with insulin C) Treatment with SGLT-2 inhibitor, thiazolidinedione or sulfonylurea D) Diabetic coma E) Renal dysfunction (eGFR<45mL/min) F) Cardiac failure G) Viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, liver cirrhosis H) Infection I) During treatment or treatment plan of malignant neoplasm J) Autoimmune disease K) Use of Steroid medicine and/or immunosuppressor L) Pregnant, possibility of pregnancy, nursing or hope to become pregnant during the study period M) In addition, when principal investigator or researcher deems inappropriate as a study subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of liver function and L/S ratio (CT) six months after the intervention
- Secondary Outcome Measures
Name Time Method Change of body weight, visceral fat amount, fasting plasma glucose (FPG), insulin, triacylglycerol (TG), non-esterified fatty acid (NEFA), HDL-cholesterol, LDL-cholesterol, lipoprotein fractionation, adiponectin, hsCPR, TNF-alpha, MCP-, MDA, typIV collagen7S, P-III-P, M2BP, the fibrosis score (NAFLD fibrosis score, FIB-4 index, APRI, BARD score, BAAT score), proinsulin/S-CPR ratio